MFDS Updates Vital Sign Sensors Rules: KC 62368-3 EMI Testing Mandatory from Oct 2026

South Korea’s Ministry of Food and Drug Safety (MFDS) has revised its Technical Review Guidelines for Vital Sign Sensors, introducing new electromagnetic interference (EMI) compliance requirements for wireless-enabled medical-grade monitoring devices. Effective 1 October 2026, the update directly affects manufacturers and exporters of wearable ECG, pulse oximetry, and other vital sign sensors with Bluetooth or Wi-Fi functionality — particularly those supplying the Korean market.

Event Overview

On 2 May 2026, MFDS published an updated version of its Technical Review Guidelines for Vital Sign Sensors. The revision mandates that all vital sign sensors incorporating wireless transmission capabilities (e.g., Bluetooth or Wi-Fi) must undergo electromagnetic compatibility (EMC) testing per KC 62368-3:2026 — specifically its anti-interference (EMI immunity) requirements. Test reports must be issued by laboratories accredited by the Korean Agency for Technology and Standards (KATS). The requirement becomes mandatory on 1 October 2026.

Industries Affected

Direct Exporters (China-based OEM/ODM manufacturers)
These companies supply finished vital sign sensor devices to Korean importers or distributors. They are directly responsible for regulatory compliance under MFDS rules. Failure to complete KC 62368-3:2026 testing before 1 October 2026 will block market entry, as MFDS requires test evidence during technical review and product registration.

Contract Manufacturers & EMS Providers
Firms assembling or integrating wireless modules into medical-grade wearables face upstream compliance pressure. If their clients require pre-certified subassemblies or full-system validation, manufacturers must ensure wireless components and firmware configurations meet KC 62368-3:2026 immunity thresholds — not just basic radio certification.

Supply Chain Service Providers (Testing Labs, Regulatory Consultants)
Service providers supporting export compliance must now verify KATS accreditation status for KC 62368-3:2026 testing — a narrower scope than general IEC 62368-1 or FCC Part 15. Demand is expected to rise for labs with both KATS recognition and experience in medical device EMC immunity testing under real-world usage conditions.

What Relevant Enterprises or Practitioners Should Focus On — And How to Respond

Confirm laboratory accreditation status for KC 62368-3:2026

KATS recognition is mandatory; generic IEC 62368-3 or legacy KC 62368-1 lab accreditation does not suffice. Exporters should obtain written confirmation from test labs that they hold current KATS authorization specifically for KC 62368-3:2026 immunity testing — including applicable test setups (e.g., conducted/radiated immunity, voltage dips, RF field exposure).

Allocate ≥4 months for full test cycle — starting now

The notice states Chinese exporters “should reserve at least 4 months for testing”. This reflects typical lead times for scheduling, pre-scan diagnostics, formal test execution, report generation, and potential retesting. Given the 1 October 2026 enforcement date, first-time applicants should initiate lab engagement no later than 1 June 2026 to mitigate delay risk.

Review wireless module selection and firmware behavior

KC 62368-3:2026 emphasizes functional immunity — i.e., the device must maintain clinical accuracy and safe operation during EMI exposure. This goes beyond signal integrity. Manufacturers should assess whether existing Bluetooth/Wi-Fi modules (and associated firmware logic for data buffering, error recovery, or fallback modes) meet performance criteria under standardized disturbance conditions.

Verify alignment between MFDS registration dossiers and test reports

MFDS requires technical documentation to reflect the exact configuration tested — including hardware revision, software version, antenna type, and wireless protocol settings. Discrepancies between submitted dossiers and test reports may trigger rejection or requests for additional verification.

Editorial Perspective / Industry Observation

Observably, this revision signals MFDS’s increasing emphasis on real-world electromagnetic resilience in connected health devices — shifting focus from basic safety (KC 62368-1) toward clinical reliability under environmental stress. Analysis shows it is less a standalone policy change and more an integration of international EMC best practices (IEC 62368-3) into Korea’s medical device regulatory framework. From an industry perspective, it functions primarily as a market access gatekeeper rather than a broad technology restriction — meaning compliance is achievable but time-bound and procedurally specific. Continued attention is warranted as MFDS may issue implementation FAQs or clarify borderline cases (e.g., low-power BLE-only devices, firmware-upgradable immunity profiles) ahead of enforcement.

Conclusion
This update underscores that wireless connectivity in medical-grade vital sign sensors is no longer treated as a peripheral feature — but as a regulated functional subsystem requiring dedicated EMI validation. For exporters and supply chain stakeholders, the timeline is fixed and non-negotiable. The requirement is not prospective guidance; it is an enforceable condition for market access. Current understanding should treat it as a hard deadline-driven compliance obligation — not a recommendation or future consideration.

Information Sources
Main source: MFDS Technical Review Guidelines for Vital Sign Sensors, revised edition published 2 May 2026.
Note: Further official clarifications (e.g., scope exclusions, transitional arrangements, or KATS-accredited lab lists) remain pending and are subject to ongoing observation.